#ASOWebinar: Obesity and Kidney Disease
Obesity is increasingly becoming a common cause for chronic kidney disease, even in the absence of diabetes or hypertension. In this webinar Dr Neil Docherty, Dr Andrew Frankel and Dr Ricardo Cohen will be discussing the pathophysiology, and medical and surgical treatment options for people with obesity and kidney disease. This will include pharmacotherapy and bariatric surgery to achieve the BMI cut offs for kidney transplantation.
18:00 Opening and introduction - Dr Alex Miras
18:05 Obesity and Chronic Kidney Disease From Association to Causation - Dr Neil Docherty
18:25 Medical treatment of chronic kidney disease associated with obesity with and without diabetes - Dr Andrew Frankel
18:50 Metabolic/Bariatric surgery as a renoprotective intervention - Dr Ricardo Cohen
19:10 Panel Q & A/ discussion
Please join us for the live panel discussion and Q & A session
Novo Nordisk has provided sponsorship to the Association for the Study of Obesity (ASO) to fully fund all costs for the development of this webinar, including creation, organisation, production and administration. Novo Nordisk has had no influence on the content and full editorial control remains the sole responsibility of ASO. None of the speakers have received a fee for their participation in this webinar, and ASO has been fully responsible for engaging with participants.
The Center for the treatment of Obesity and Diabetes
Hospital Oswaldo Cruz, Sao Paulo, Brasil
Director: The Center for the treatment of Obesity and Diabetes, Hospital Oswaldo Cruz, Sao Paulo, Brasil
Past President - Brazilian Society for Bariatric and Metabolic Surgery (2011-2012)
Past President -International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO), Latin American Chapter (2018-2019)
University College, Dublin
I am Associate Professor (Anatomy) at The University College Dublin (UCD) School of Medicine and Principal Investigator at The UCD Diabetes Complications Research Centre at The UCD Conway Institute. I am interested in the role of obesity and diabetes as modifiable risk factors for the development and progression of chronic kidney disease. To this end, I co-lead translational research studies at The UCD Metabolic Medicine group wherein we work to identify and characterise optimised surgical and medical approaches for the treatment of obesity, type 2 diabetes and associated chronic kidney disease.
Imperial College, London
Dr Andrew Frankel has been working as a consultant nephrologist at Imperial College Healthcare NHS trust since 1995. He has experience in managing all aspects of kidney disease but has a particular interest in relation to the management of diabetes in the context of kidney disease. Over the years he has maintained a significant research interest in relation to diabetes and kidney, both in terms of how diabetes affects the kidneys leading to deterioration in kidney function, but also in relation to how the presence of kidney disease influences the management of diabetes. Because of this experience, Dr Frankel has played a significant role in the development of national guidelines on the management of diabetes in the context of kidney disease. In addition he is now cochairing the guideline group producing a national guidelines on the use of SGLT2I in people with chronic kidney disease He is a regular speaker both locally and nationally and indeed internationally in relation to matters pertaining to diabetes and the kidney. In collaboration with colleagues within Imperial College and indeed both nationally and internationally, Dr Frankel has published research in relation to assessment of renal complications in patients with diabetes and obesity. Dr Frankel has significant commitment to and experience in relation to training the next generation of doctors, having been the director Imperial’s Foundation School from its inception to 2010, London lead for Foundation Training and Postgraduate Dean for south London from 2013 and 2018.
Imperial College, London
Alex Miras is interested in the mechanisms through which lifestyle interventions, pharmacotherapy, bariatric surgery and medical devices improve weight, metabolic control and diabetes-related microvascular complications.